Doubt Cast On Claim Of 'Hints' Of Life On Faraway Planet
When astronomers announced last month they might have discovered the most promising hints of alien life yet on a distant planet, the rare good news raised hopes humanity could soon learn we are not alone in the universe.
But several recent studies looking into the same data have found that there is not enough evidence to support such lofty claims, with one scientist accusing the astronomers of "jumping the gun".
The debate revolves around the planet K2-18b, which is 124 light years away in the Leo constellation.
The planet is thought to be the right distance from its star to have liquid water, making it a prime suspect in the search for extraterrestrial life.
Last month, astronomers using the James Webb Space Telescope made headlines by announcing they had detected hints of the chemicals dimethyl sulfide (DMS) and dimethyl disulfide (DMDS) on the planet.
These chemicals are only produced by life such as marine algae on Earth, meaning they are considered potential "biosignatures" indicating life.
The astronomers, led by Cambridge University's Nikku Madhusudhan, expressed caution about the "hints" of a biosignature, emphasising they were not claiming a definitive discovery.
Their detection had reached a three-sigma level of statistical significance "which means there is still a three in 1,000 chance of this being a fluke," Madhusudhan said at the time.
Biosignatures 'Vanish'
Two of Madhusudhan's former students, Luis Welbanks of Arizona State University and Matthew Nixon of Maryland University, were among the researchers who have since re-analysed the data behind the announcement.
When deploying other statistical models, "claims of a potential biosignature detection vanish", according to their preprint study published online late last month.
Like the other papers since the April announcement, it has not been peer-reviewed.
In one model, Welbanks and colleagues expanded the number of possible chemicals that could explain the signals detected by Webb to 90 from the original 20.
More than 50 received a "hit", Welbanks told AFP.
"When you detect everything, did you really detect anything?" he asked.
They are not saying the planet definitely does not have DMS -- just that more observations are needed, Welbanks added.
'Arguments Are Healthy'
Madhusudhan welcomed the robust debate, saying that remaining open to all possibilities is an essential part of the scientific method.
"These sort of arguments are healthy," he told AFP.
His team even went further, releasing their own preprint study last week that expanded the number of chemicals even further to 650.
The three most "promising" chemicals they found included DMS but not DMDS -- a major part of the team's announcement in April.
The other two chemicals were diethyl sulfide and methyl acrylonitrile, the latter of which is toxic.
Madhusudhan admitted that these little-known chemicals are likely not "realistic molecules" for a planet like K2-18b.
Welbanks pointed out that "in the span of a month -- with no new data, with no new models, with no new laboratory data -- their entire analysis changed".
'Closest We Have Ever Been'
Telescopes observe such far-off exoplanets when they cross in front of their star, allowing astronomers to analyse how molecules block different wavelengths of light streaming through their atmosphere.
Earlier this week, a paper led by Rafael Luque at the University of Chicago combined Webb's observations of K2-18b in both the near-infrared and mid-infrared wavelengths of light.
It also found "no statistical significance for DMS or DMDS", the paper said.
An earlier paper by Oxford astrophysicist Jake Taylor using a basic statistical test also found no strong evidence for any biosignatures.
Madhusudhan dismissed the latter paper, saying the simple exercise did not account for observing physical phenomena.
He also stood by his research, saying he was "just as confident" in the work as he was a month ago.
More data about K2-18b will come in over the next year which should offer a much clearer picture, Madhusudhan added.
Even if the planet does have DMS, it is not a guarantee of life -- the chemical has been detected on a lifeless asteroid.
However, many researchers do believe that space telescopes could one day collect enough evidence to identify alien life from afar.
"We are the closest we have ever been" to such a moment, Welbanks said.
"But we have to use the frameworks that are in place and build up (evidence) in a reliable method, rather than using non-standard practices and jumping the gun -- as has been done in this particular case," Nixon added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
an hour ago
- United News of India
Rare gas detected on distant exoplanet sheds light on planet formation: study
Sydney, June 2 (UNI) Astronomers have detected silicon monoxide gas in the atmosphere of a planet 850 lightyears from Earth, the first time the gas has ever been observed on any planet, including those in the solar system. According to a press release from the University of Newcastle in Australia on Monday, the research offers unprecedented insight into the formation and atmospheric chemistry of exoplanet WASP-121b, also known as Tylos. The planet, discovered in 2015, is an ultra-hot gas giant similar in size to Jupiter but far hotter, with temperatures exceeding 2,500 degrees Celsius, the release said. The international team, led by Tom Evans-Soma from the University of Newcastle and involved 18 institutions across Australia, Germany, the United States, Britain and India, used NASA's James Webb Space Telescope to observe Tylos continuously for 40 hours, which is the most comprehensive observation ever made of an exoplanet completing a full orbit, it said. Over 3,500 exposures, about one every minute, were captured, allowing researchers to analyze both the dayside and nightside atmospheres, said the study published in Nature Astronomy. While expected molecules like water vapor and carbon monoxide were found, the surprising detection of silicon monoxide and methane, rare on such hot planets, challenges existing atmospheric models, Evans-Soma said. The study suggests Tylos formed in a cold, distant region rich in ice and rocky material before migrating closer to its star, where intense heat vaporized the rocks into silicon monoxide, a planet born in ice and forged in fire, he said. Though Tylos is uninhabitable, the study advances the search for Earth-like planets by improving techniques to detect potential signs of life in distant atmospheres, he added. UNI XINDUA AKT SSP
NDTV
an hour ago
- NDTV
Milky Way May Not Be Destroyed In Galactic Smash-Up After All
The Milky Way may not have a catastrophic collision with another huge galaxy as has been predicted, computer simulations revealed Monday, giving our home galaxy a coin-flip chance of avoiding destruction. But don't worry either way: no galactic smash-up is expected for billions of years, long after our ageing Sun will have burnt away all life on Earth. The Milky Way and the even-larger galaxy Andromeda are speeding towards each other at 100 kilometres (60 miles) a second, and scientists have long predicted they will collide in around 4.5 billion years. That would be bad news for our neighbourhood. Previous research has suggested that the Sun -- and our Earth -- could wind up in the centre of this newly merged "Milkomeda" galaxy and get sucked into its supermassive black hole. Alternatively, the Sun could be shot out into the emptiness of intergalactic space. However "proclamations of the impending demise of our galaxy seem greatly exaggerated", according to a new study in the journal Nature Astronomy. There is only a roughly 50 percent chance the Milky Way and Andromeda will smash into each other in the next 10 billion years, the international team of astrophysicists determined. "It's basically a coin flip," lead study author Till Sawala of the University of Helsinki told AFP. The researchers ran more than 100,000 computer simulations of our universe's future, using new observations from space telescopes. A galaxy merger in the next five billion years is "extremely unlikely", Sawala said. Much more likely is that the galaxies will zoom relatively close to each other -- say, a little under 500,000 light years away. In only half of the simulations did dark matter then eventually drag the two galaxies together into a cataclysmic embrace. But this would likely only occur in around eight billion years -- long after our Sun has died, the researchers found. "So it could be that our galaxy will end up destroyed," Sawala said. "But it's also possible that our galaxy and Andromeda will orbit one another for tens of billions of years -- we just don't know." Galaxy's Fate 'Open' "The fate of our galaxy is still completely open," the study summarised. The researchers emphasised that their findings did not mean that previous calculations were incorrect, just that they had used newer observations and taken into account the effect of more satellite galaxies. Future data releases from Europe's recently retired Gaia space telescope as well as Hubble could provide a definitive answer to this question within the next decade, Sawala predicted. How much all this all matters to us is a matter of debate. The Sun is expected to make Earth inhospitable to life in around a billion years. "We might have some emotional attachment" to what happens after we're gone, Sawala said. "I might prefer the Milky Way not to collide with Andromeda, even though it has absolutely no relevance to my own life -- or the lives of my children or great-great grandchildren."
NDTV
3 hours ago
- NDTV
New Hope For Patients With Less Common Breast Cancer
Virginia, United States: A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 percent of all breast cancer cases. HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart Bomb' This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Ms Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Ms Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 Percent Risk Reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Ms Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
